The short version of NMN fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-17 and is reviewed periodically as new material appears.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Common name; beta form often denoted beta-NMN |
| Chemical formula | C11H15N2O8P | As free acid; salt forms differ |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | For beta-nicotinamide mononucleotide |
| Biochemical role | NAD+ intermediate | Participates in the salvage biosynthesis pathway |
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
=== Histology === Histological structure of type 1 consists of tight tissue fibers and loose connective tissues. The surrounding loose fibers are rich in blood vessels with pathways for nerves. Tendinous fibers are rarely found and are in single direction. Type 2 juncturae tendinum is also composed of single direction fibers like type 1, but with thicker bundles. Histological structure of the type 3 juncturae is denser and thicker than type 2 juncturae and tendinous fibers are arranged in two layers. Tendinous fibers of the type 3 show crosswise direction with single direction and oblique bundles. No muscular tissue is observed in any type of the juncturae tendinum.
To demonstrate just how deadly this species is, an estimate was made on the number of mice and adult human fatalities it is capable of causing in a single bite that yields the maximum dose of 400 mg. Based on the study by Ernst and Zug et al. 1996, which listed the LD50 of the coastal taipan at 0.106 mg SC and a venom yield of 400 mg, this would be sufficient to kill 208,019 mice and 59 adult humans in a single bite that delivers 400 mg of venom. The venom apparatus of this species is well developed. The fangs are the longest of any Australian elapid snake, being up to 1.2 cm (0.5 in) long, and are able to be brought forward slightly when a strike is contemplated. Coastal taipans can inject large amounts of highly toxic venom deep into the tissue. Its venom contains primarily taicatoxin, a highly potent neurotoxin known to cause hemolytic and coagulopathic reactions. The venom affects the nervous system and the blood's ability to clot, and bite victims may experience headache, nausea and vomiting, collapse, convulsions (especially in children), paralysis, internal bleeding, myolysis (destruction of muscle tissue) and kidney damage. In a single study done in Papua New Guinea, 166 patients with enzyme immunoassay-proven bites by Papuan taipans (Oxyuranus scutellatus canni) were studied in Port Moresby, Papua New Guinea. Of the 166 bite victims, 139 (84%) showed clinical evidence of envenoming: local signs were trivial, but the majority developed hemostatic disorders and neurotoxicity.
The two substrates of this enzyme are geraniol and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are geranial, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is geraniol:NADP+ oxidoreductase.
Many fast food chains stopped use of the product after the controversy arose, or stated that they had not used the product before. In April 2012, the Concord Monitor reported increased business in some small neighborhood markets where the product's use was less likely, due to consumer concerns about the additive. In March 2012, 70% of ground beef in the U.S. contained lean finely textured beef, and a year later, in March 2013, the amount was estimated by meat industry officials to be at approximately 5%. This significant reduction is due in part to the extensive media coverage that began in March 2012 about the additive. Kroger Co. and Supervalu Inc. stopped using the additive. On March 25, 2012, BPI announced it would suspend operations at three of its four plants, being in "crisis planning". The three plants produced a total of about 900,000 pounds of the product per day. BPI said it lost contracts with 72 customers, many over the course of one weekend, and production decreased from 5 million pounds of LFTB per week to below one million pounds a week at the nadir (lowest point of production). Effective May 25, 2012, BPI closed three of its four plants, including one in Garden City, Kansas, lost more than $400 million in sales, and laid off 700 workers. Production decreased to less than 2 million pounds in 2013. Cargill also significantly cut production of finely textured beef and in April 2012 "warned [that] the public's resistance to the filler could lead to higher hamburger prices this barbecue season".
Sources: en.wikipedia.org
The possibility that dinosaurs were the ancestors of birds was first suggested in 1868 by Thomas Henry Huxley. After the work of Gerhard Heilmann in the early 20th century, the theory of birds as dinosaur descendants was abandoned in favor of the idea of them being descendants of generalized thecodonts, with the key piece of evidence being the supposed lack of clavicles in dinosaurs. However, as later discoveries showed, clavicles (or a single fused wishbone, which derived from separate clavicles) were not actually absent; they had been found as early as 1924 in Oviraptor, but misidentified as an interclavicle. In the 1970s, John Ostrom revived the dinosaur–bird theory, which gained momentum in the coming decades with the advent of cladistic analysis, and a great increase in the discovery of small theropods and early birds. Of particular note have been the fossils of the Jehol Biota, where a variety of theropods and early birds have been found, often with feathers of some type. Birds share over a hundred distinct anatomical features with other theropod dinosaurs. They are most closely allied with maniraptoran coelurosaurs. A minority of scientists, most notably Alan Feduccia and Larry Martin, have proposed other evolutionary paths, including revised versions of Heilmann's basal archosaur proposal, or that maniraptoran theropods are the ancestors of birds but themselves are not dinosaurs, only convergent with dinosaurs.
A common combination is gas chromatography-mass spectrometry (GC/MS or GC-MS). In this technique, a gas chromatograph is used to separate different compounds. This stream of separated compounds is fed online into the ion source, a metallic filament to which voltage is applied. This filament emits electrons which ionize the compounds. The ions can then further fragment, yielding predictable patterns. Intact ions and fragments pass into the mass spectrometer's analyzer and are eventually detected. However, the high temperatures (300 °C) used in the GC-MS injection port (and oven) can result in thermal degradation of injected molecules, thus resulting in the measurement of degradation products instead of the actual molecule(s) of interest.
=== The name === The word Pseudomonas means false unit, being derived from the Greek words pseudēs (Greek: ψευδής – false) and monas (Latin: monas, from Greek: μονάς – a single unit). The word was used early in the history of microbiology to refer to germs. The specific name fluorescens refers to the microbe's secretion of a soluble fluorescent pigment called pyoverdin, which is a type of siderophore.
As glucose increases, the production of insulin increases, which thereby increases the utilization of the glucose, which maintains the glucose levels in an efficient manner and creates an oscillatory behavior.
The chemical names were based on the side chains of the compounds. In 1948, Chain introduced the chemical names as standard nomenclature, remarking that this would "make the nomenclature as far as possible unambiguous". In Kundl, Tyrol, Austria, in 1952, Hans Margreiter and Ernst Brandl of Biochemie developed the first acid-stable penicillin for oral administration, penicillin V. American chemist John C. Sheehan at the Massachusetts Institute of Technology (MIT) completed the first chemical synthesis of penicillin V in 1957. Sheehan had started his studies into penicillin synthesis in 1948, and during these investigations developed new methods for the synthesis of peptides, as well as new protecting groups—groups that mask the reactivity of certain functional groups. Although the initial synthesis developed by Sheehan was not appropriate for mass production of penicillins, one of the intermediate compounds in Sheehan's synthesis was 6-aminopenicillanic acid (6-APA), the nucleus of penicillin. An important development was the discovery of 6-APA itself. In 1957, researchers at the Beecham Research Laboratories in Surrey isolated 6-APA from the culture media of P. chrysogenum. 6-APA was found to constitute the core nucleus of penicillin (and subsequently many β-lactam antibiotics) and was easily chemically modified by attaching side chains through chemical reactions. The discovery was published in Nature in 1959. This paved the way for new and improved drugs as all semisynthetic penicillins are produced from chemical manipulation of 6-APA.
Sources: en.wikipedia.org
==== Eye drops ==== Chloramphenicol is used in topical preparations (ointments and eye drops) for the treatment of bacterial conjunctivitis. Isolated case reports of aplastic anaemia following use of chloramphenicol eyedrops exist, but the risk is estimated to be of the order of less than one in 224,716 prescriptions. In Mexico, this is the treatment used prophylactically in newborns for neonatal conjunctivitis.
== Etymology == The name probably comes from a confusion between the Ricinus plant that produces it and another plant, the Vitex agnus-castus. An alternative etymology, though, suggests that it was used as a replacement for castoreum.
These early experiments with animal blood provoked a heated controversy in Britain and France. Finally, in 1668, the Royal Society and the French government both banned the procedure. The Vatican condemned these experiments in 1670. Blood transfusions fell into obscurity for the next 150 years.
cleavage 1. The physical separation of a dividing parent cell into multiple individual daughter cells. 2. In embryology, the series of mitotic divisions by which a fertilized ovum is divided, without an accompanying overall change in size, into a ball of smaller cells constituting the early embryo.
Stage I, 6 h to 14 h after last dose: Drug craving, anxiety, irritability, perspiration, and mild to moderate dysphoria Stage II, 14 h to 18 h after last dose: Yawning, heavy perspiration, mild depression, lacrimation, crying, headaches, runny nose, dysphoria, also intensification of the above symptoms, "yen sleep" (a waking trance-like state) Stage III, 16 h to 24 h after last dose: Increase in all of the above, dilated pupils, piloerection (goose bumps), muscle twitches, hot flashes, cold flashes, aching bones and muscles, loss of appetite, and the beginning of intestinal cramping Stage IV, 24 h to 36 h after last dose: Increase in all of the above including severe cramping, restless legs syndrome, loose stool, insomnia, elevation of blood pressure, fever, increase in frequency of breathing and tidal volume, tachycardia (elevated pulse), restlessness, nausea Stage V, 36 h to 72 h after last dose: Increase in all of the above, fetal position, vomiting, free and frequent liquid diarrhea, weight loss of 2 kg to 5 kg per 24 h, increased white cell count, and other blood changes Stage VI, after completion of above: Recovery of appetite and normal bowel function, beginning of transition to post-acute withdrawal symptoms that are mainly psychological, but may also include increased sensitivity to pain, hypertension, colitis or other gastrointestinal afflictions related to motility, and problems with weight control in either direction In advanced stages of withdrawal, ultrasonographic evidence of pancreatitis has been demonstrated in some patients and is presumably attributed to spasm of the pancreatic sphincter of Oddi. The withdrawal symptoms associated with morphine addiction are usually experienced shortly before the time of the next scheduled dose, sometimes within as early as a few hours (usually 6 h to 12 h) after the last administration. Early symptoms include watery eyes, insomnia, diarrhea, runny nose, yawning, dysphoria, sweating, and, in some cases, a strong drug craving. Severe headache, restlessness, irritability, loss of appetite, body aches, severe abdominal pain, nausea and vomiting, tremors, and even stronger and more intense drug craving appear as the syndrome progresses. Severe depression and vomiting are common. During the acute withdrawal period, systolic and diastolic blood pressures increase, usually beyond premorphine levels, and heart rate increases, which have potential to cause a heart attack, blood clot, or stroke. Chills or cold flashes with goose bumps alternating with flushing (hot flashes), kicking movements of the legs, and excessive sweating are also characteristic symptoms. Severe pains in the bones and muscles of the back and extremities occur, as do muscle spasms. At any point during this process, a suitable narcotic can be administered that will dramatically reverse the withdrawal symptoms. Major withdrawal symptoms peak between 48 h and 96 h after the last dose and subside after about 8 to 12 days. Sudden discontinuation of morphine by heavily dependent users who are in poor health is rarely fatal. Morphine withdrawal is considered less dangerous than alcohol, barbiturate, or benzodiazepine withdrawal. The psychological dependence associated with morphine addiction is complex and protracted. Long after the physical need for morphine has passed, addicts will usually continue to think and talk about the use of morphine (or other drugs) and feel strange or overwhelmed coping with daily activities without being under the influence of morphine. Psychological withdrawal from morphine is usually a long and painful process. Addicts often experience severe depression, anxiety, insomnia, mood swings, forgetfulness, low self-esteem, confusion, paranoia, and other psychological problems. Without intervention, the syndrome will run its course, and most of the overt physical symptoms will disappear within 7 to 10 days including psychological dependence. A high probability of relapse exists after morphine withdrawal when neither the physical environment nor the behavioral motivators that contributed to the abuse have been altered. Testimony of morphine's addictive and reinforcing nature is its relapse rate. Users of morphine have one of the highest relapse rates among all drug users, ranging up to 98% in the estimation of some medical experts.
Sources: en.wikipedia.org
Nicotinamide mononucleotide is a nucleotide intermediate in the biosynthesis of NAD+. It consists of nicotinamide attached to a ribose phosphate unit. NMN occurs naturally in cells and is present at low levels in some foods.
NMN is a direct precursor in the NAD+ salvage pathway. Enzymes called NMNAT convert NMN into NAD+, a coenzyme used in metabolism and cell signaling. Raising NMN may increase NAD+ in some experimental settings, but the effect depends on tissue and organism.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Cells can convert nicotinamide riboside into NMN, and both compounds feed into NAD+ production through overlapping routes.
NMN is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis. It consists of nicotinamide attached to a ribose phosphate unit. Cells produce it through the salvage pathway.